Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease

Daniel Bradshaw*, Iga Abramowicz, Stephen Bremner, Sumita Verma, Yvonne Gilleece, Sarah Kirk, Mark Nelson, Rosalie Housman, Helena Miras, Chloe Orkin, Ashini Fox, Michael Curnock, Louise Jennings, Mark Gompels, Emily Clarke, Rachel Robinson, Pauline Lambert, David Chadwick, Nicky Perry

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Fingerprint

Dive into the research topics of 'Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease'. Together they form a unique fingerprint.

Medicine and Dentistry